Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

7

Enrollment

NIH

Sponsor class

Conditions

Pulmonary Alveolar Proteinosis (PAP)
Severe Mucocutaneous Candidiasis

Interventions

DRUG: Rituximab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)